Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 8/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17689059 | 0.78 | DDR1 (0.39) | DDR1MPOSLC6A4MEN1MAPT | |
| SCHEMBL14495394 | 0.77 | P2RX7 (0.47) | ICMTMPOSLC6A4 | |
| SCHEMBL1115269 | 0.77 | MAPK8 (0.52) | ICMTMPOSLC6A4MAPK8 | |
| SCHEMBL30148003 | 0.77 | MAPK8 (0.52) | ICMTMPOSLC6A4MAPK8 | |
| SCHEMBL28037697 | 0.77 | CA3 (0.45) | ICMTMPOSLC6A4MEN1MAPT | |
| SCHEMBL2526394 | 0.77 | MPO (0.41) | DDR1MPOSLC6A4 | |
| SCHEMBL1569021 | 0.75 | LMNA (0.47) | SLC6A4MEN1MAPTKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL8894497 | 0.75 | IDO1 (0.52) | ICMTMPOSLC6A4MAPK8 | |
| SCHEMBL28148702 | 0.75 | ICMT (0.47) | ICMTMPOSLC6A4MAPK8 | |
| SCHEMBL4068010 | 0.74 | CES2 (0.42) | MEN1MAPTRAB9AKMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | ICMT 1397/4885DDR1 3524/4885MPO 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.